- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
- A new generation of virus-free CAR-T cell therapy
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
New immunotherapy for lung cancer reduces disease progression by 38%.
First-line treatment of lung cancer TIGIT antibody immune combination therapy reduces the risk of disease progression by 38%.
On December 10, 2021, Genentech, a Roche subsidiary, announced that the new cancer immunotherapy tiragolumab targeting TIGIT, combined with the PD-L1 inhibitor atezolizumab, will be the first-line treatment for PD- Positive results were obtained in Phase 2 clinical trials in patients with L1-positive metastatic non-small cell lung cancer (NSCLC).
At a median follow-up time of 2.5 years, the combination of tiragolumab/atilizumab resulted in a significant and continuous improvement in the progression-free survival (PFS) of patients compared with atilizumab monotherapy.
TIGIT (T cell immunoreceptor with Ig and ITIM domains) is called T cell immunoglobulin and ITIM domain protein. It is an immune checkpoint protein mainly expressed on the surface of T cells and natural killer (NK) cells.
The press release states that tiragolumab is the first anti-TIGIT therapy to be granted breakthrough therapy designation by the US FDA.
Blocking the TIGIT signal pathway with tiragolumab may enhance the body’s immune response to cancer cells and improve anti-tumor activity.
The latest results show that when the median follow-up time is 2.5 years:
In the intent-to-treat (ITT) population (n=67), compared with atelizumab monotherapy (median PFS=3.9 months), the tiragolumab/atelizumab combination makes the patient’s disease progression or The risk of death was reduced by 38%, the median PFS was 5.6 months (HR=0.62, 95% CI: 0.42–0.91), and the overall response rate (ORR) was improved (38.8% VS. 20.6%).
Exploratory analysis in patients with high PD-L1 expression (TPS≥50%) (n=29) showed that compared with atelizumab monotherapy (median PFS=4.1 months), patients’ disease The risk of progression or death risk was reduced by 71%, the median PFS was 16.6 months (HR=0.29, 95% CI: 0.15–0.53), and the ORR was significantly improved (69% VS. 24.1%).
In the secondary end point of the overall survival (OS) trial, the tiragolumab/atelizumab combination also brought benefits to the ITT population, with a median OS of 23.2 months (14.5 months for the control group) (HR= 0.69, 95% CI: 0.44–1.07).
The specific results of the test are shown in the table below:
Table source: Reference materials
Dr. Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development, said: These encouraging results indicate that the combination of anti-TIGIT antibodies and anti-PD-L1 cancer immunotherapy may represent a new approach to addressing the unmet need for cancer. We look forward to the results of phase 3 clinical trials in lung cancer and other challenging tumor types.
 New Data From the Phase II CITYSCAPE Trial Show Encouraging Results With Genentech’s Novel Anti-TIGIT Tiragolumab Plus Tecentriq. Retrieved December 10, 2021
New immunotherapy for lung cancer reduces disease progression by 38%
(source:internet, reference only)